• 1. The First Clinical Medical College, Lanzhou University, Lanzhou 730000, P. R. China;
  • 2. General Surgery Department of Gansu Provincial People’s Hospital, Lanzhou 730099, P. R. China;
  • 3. Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, P. R. China;
  • 4. Key Laboratory of Molecular Diagnosis and Precision Medicine for Surgical Oncology in Gansu Province, Lanzhou 730000, P. R. China;
CAI Hui, Email: caialonteam@163.com
Export PDF Favorites Scan Get Citation

Objective To investigate the correlation between different RAS/BRAF mutation sites and the clinicopathological characteristics, metastatic sites, and prognosis of patients with colorectal cancer. Methods A retrospective analysis was conducted on the clinicopathological data of 415 patients with stage Ⅰ –Ⅲ microsatellite stability (MSS) colorectal cancer who underwent radical surgery at the Department of Colorectal Surgery, The First Affiliated Hospital of Zhejiang University, and the Department of General Surgery, Gansu Provincial People’s Hospital, from March 1, 2017, to October 1, 2022, and had next-generation sequencing data. According to the presence and sites of RAS/BRAF mutations, patients were divided into five groups: RAS/BRAF wild-type group, KRAS G12 codon mutation group, KRAS G13 codon mutation group, BRAFV600E mutation group, and other RAS codon mutation group. The clinicopathological characteristics and prognostic differences between the four groups of RAS/BRAF mutant colorectal cancer patients and the RAS/BRAF wild-type colorectal cancer patients were compared. Results Among stage Ⅰ –Ⅲ MSS colorectal cancer patients, there were 166 cases (40.0%) of wild-type RAS/BRAF without mutation, 124 cases (29.9%) of KRAS G12 mutation, 55 cases (13.3%) of KRAS G13 mutation, 23 cases (5.5%) of BRAFV600E mutation, and 47 cases (11.3%) of other RAS codon mutations. Clinicopathological characteristics analysis revealed that BRAFV600E mutation was associated with mucinous adenocarcinoma (P=0.033). Compared with the wild-type group, KRAS G12 mutation could increase the probability of metachronous lung metastasis (P=0.003) and reduce the probability of metachronous liver metastasis (P=0.013); the KRAS G13 mutation and other RAS mutations could increase the probability of metachronous lung metastasis (P=0.004, P=0.006). Univariate and multivariate Cox proportional hazards regression analysis showed that among the RAS/BRAF codon mutations, only KRAS G13 mutation was an independent prognostic factor for poor prognosis in stage Ⅰ –Ⅲ colorectal cancer. Conclusions Different RAS/BRAF gene codon mutations are associated with distinct clinicopathological characteristics and organ metastatic sites in colorectal cancer. KRAS G13 codon mutation is an independent prognostic factor for poor prognosis in stage Ⅰ –Ⅲ colorectal cancer. It is recommended that routine detection of RAS/BRAF gene site mutations should be performed in stage Ⅰ –Ⅲ colorectal cancer patients to guide the follow-up management and help clinicians make rational clinical decisions after tumor recurrence.

Citation: ZHANG Xiang, JIANG Weiqin, HUA Hanju, LIU Shuo, LIAO Tianyi, CAI Hui. Comparison of clinicopathological characteristics, metastatic sites, and prognosis of Ⅰ –Ⅲ stage MSS type colorectal cancer patients with different RAS/BRAF codon mutation. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(6): 682-689. doi: 10.7507/1007-9424.202312043 Copy

  • Previous Article

    The predictive value of preoperative NRS2002 score for survival in patients with colorectal cancer: an analysis based on the DACCA database
  • Next Article

    Preliminary verification of animal model of benign esophageal stricture caused by gastroesophageal reflux in rats